Eisai’s Alzheimer’s drug Leqembi set for China rollout
Eisai plans to introduce its groundbreaking Alzheimer’s drug, Leqembi, to 1,500 people in China this year, with expectations of significant growth in 2025 as diagnosis [more…]
Eisai plans to introduce its groundbreaking Alzheimer’s drug, Leqembi, to 1,500 people in China this year, with expectations of significant growth in 2025 as diagnosis [more…]
In a sobering turn of events, Japan has reported its first death from mpox, a viral disease that has been causing concern since its first [more…]
In a monumental stride forward in medical science, the U.S. Food and Drug Administration (FDA) has granted approval for the first gene-editing treatment for sickle [more…]
In a concerning turn of events, South Korea is grappling with a resurgence of highly pathogenic avian influenza (AI) as health authorities confirmed a second [more…]
In the heart of Rio de Janeiro, where the rhythms of samba once danced in harmony with a groundbreaking movement to provide affordable HIV treatment, [more…]
Japan, known for its rich history and advanced technology, is facing a daunting challenge as its population continues to gray and decline. Government data has [more…]
In a groundbreaking development, the Food and Drug Administration (FDA) has granted approval to Eli Lilly’s blockbuster drug, tirzepatide, for the treatment of obesity in [more…]
Novo Nordisk, a global pharmaceutical company known for its innovative treatments in diabetes care and obesity management, recently announced an encouraging development regarding the accessibility [more…]
In a growing health crisis, a multistate salmonella outbreak has swept across 22 U.S. states, resulting in at least 73 reported cases and 15 hospitalizations, [more…]
In a significant development, GlaxoSmithKline (GSK) announced promising results from a late-stage clinical trial for their vaccine, Arexvy, which exhibits the potential to protect adults [more…]